Showing results (91-100 of 176) with videos related to

Sort By:
Pageof 18
Cancer Research|April 6, 2006
Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABLMyriam Adam, Vanda Pogacic, Marina Bendit, et al.
Haematologica|March 9, 2010
ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusionsKatrien Van Roosbroeck, Jan Cools, Daan Dierickx, et al.
Scientific Reports|June 5, 2015
A RP-UFLC Assay for Protein Tyrosine Phosphatases: Focus on Protein Tyrosine Phosphatase Non-Receptor Type 2 (PTPN2)Romain Duval, Linh-Chi Bui, Jérémy Berthelet, et al.
Haematologica|March 7, 2008
In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemiaKim De Keersmaecker, Idoya Lahortiga, Nicole Mentens, et al.
Genes, Chromosomes & Cancer|February 19, 2026
IRF2BP2::JAK2 Defines a Novel Kinase-Activating Fusion in Pediatric T-Cell Acute Lymphoblastic LeukemiaFatimah B Jalud, Tasnia Ibnat, Kaitlyn Kew, et al.
Blood|February 17, 2005
Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32)Kim De Keersmaecker, Carlos Graux, Maria D Odero, et al.
Experimental Hematology|January 11, 2014
Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRAIrina Sadovnik, Els Lierman, Barbara Peter, et al.
The Journal of Biological Chemistry|October 9, 2015
Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor SpecificitiesElisabeth Losdyck, Tekla Hornakova, Lorraine Springuel, et al.
Molecular Oncology|March 13, 2014
The tyrosine phosphatase SHP2 is required for cell transformation by the receptor tyrosine kinase mutants FIP1L1-PDGFRα and PDGFRα D842VLaura A Noël, Florence A Arts, Carmen P Montano-Almendras, et al.
Experimental Hematology|February 6, 2024
In vivo activity of the second-generation proteasome inhibitor ixazomib against pediatric T-cell acute lymphoblastic leukemia xenograftsJoanna Randall, Kathryn Evans, Ben Watts, et al.
Pageof 18